Share page on FacebookShare page on TwitterShare page on LinkedIn
ICON plc
  • Services

    Services

    Our services span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.

    Read More
    Services
    Adaptive TrialsClinical Research ServicesConsultingEarly PhaseFunctional Services ProvisionLaboratoriesLanguage ServicesMedical ImagingReal World IntelligenceSite & Patient Solutions Value Access Outcomes
    Clinical trials during COVID-19.
    COVID-19 clinical operations

    Clinical trials during COVID-19.

    Bringing the clinical trial to the patient with innovation and in-home solutions.
    Decentralised & hybrid clinical solutions

    Bringing the clinical trial to the patient with innovation and in-home solutions.

  • Sectors

    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read More
    Sectors
    BiosimilarsBiotechGovernment & Public Health SolutionsMedical DevicePharmaceuticals
    A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.
    The IVDR journey

    A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.

    Serving governments, multinational public health organisations, and global NGOs.
    Government and Public Health Solutions

    Serving governments, multinational public health organisations, and global NGOs.

  • Therapeutics

    Therapeutics

    We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.

    Read More
    Therapeutics
    CardiovascularCell and Gene TherapiesCentral Nervous SystemEndocrine & Metabolic DisordersGenomicsInfectious DiseasesInternal Medicine & ImmunologyMedical DeviceRare & Orphan DiseasesTransplant ImmunologyWomen's Health
    ICON has conducted hundreds of clinical studies in both solid and haematological tumours, including experience with CAR-T therapies.
    Oncology

    ICON has conducted hundreds of clinical studies in both solid and haematological tumours, including experience with CAR-T therapies.

    ICON has recently led the development of 17 vaccines resulting in FDA/EMA approvals. We are currently working on a number of COVID-19 vaccine trials.
    Vaccines

    ICON has recently led the development of 17 vaccines resulting in FDA/EMA approvals. We are currently working on a number of COVID-19 vaccine trials.

  • Innovation

    Innovation

    We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.

    Read More
    Innovation
    FIRECRESTSafety Reporting SolutionOne SearchEvidence PlatformFLEX ADVANTAGE Medical Imaging TechnologyNONMEM ICONIKPDx-POPPubsHubSIMS
    With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.
    FIRECREST

    With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.

    Connecting patients with the right trial in the right location.
    Patient Engagement Platform

    Connecting patients with the right trial in the right location.

  • Insights

    Insights

    BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.

    Read More
    Insights
    Digital Disruption Patient CentricityRegulatory IntelligenceTransforming TrialsValue Based HealthcareBlogVideosWebinar Channel
    Aggregated news on COVID-19 clinical trials.
    Coronavirus Observatory

    Aggregated news on COVID-19 clinical trials.

    Patient focused research for better outcomes.
    Decentralised & hybrid clinical trials

    Patient focused research for better outcomes.

  • News & Events

    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read More
    News & Events
    Press ReleasesIn the NewsEventsMediakitSocial MediaAwards
    Trial capabilities key to enabling agility and speed in global study involving 44,000 subjects.
    ICON supports Pfizer and BioNTech on COVID-19 vaccine trial

    Trial capabilities key to enabling agility and speed in global study involving 44,000 subjects.

    3 February, 2021
    Webinar: FT Digital Dialogues: Building resilience in pharma R&D by decentralising and digitising

    3 February, 2021

  • About ICON

    About ICON

    Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.

    Read More
    About ICON
    Company HistoryICON in Asia PacificICON in Latin AmericaLeadershipQuality
    ICON is committed to making a positive impact on our people, environment and our community.
    Environmental, Social & Governance

    ICON is committed to making a positive impact on our people, environment and our community.

    Partners making a difference.
    ICON and You

    Partners making a difference.

  • Careers
  • Investors
  • Investigators
  • Patients
  • Contact
  • EN | 日本語
  1. Home
  2. News & Events
  3. Press Releases

Press Releases

  • 22 July 2020

    ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting

    Dublin, Ireland, July 22, 2020

  • 22 July 2020

    ICON Reports Second Quarter 2020 Results

    Quarter 2 reported revenue of $620.2 million representing a year on year decrease of 10.8% or 10.3% on a constant currency basis.

  • 27 May 2020

    ICON plc to Present at Jefferies Virtual Healthcare Conference

    Tuesday, June 2, 2020

  • 13 May 2020

    ICON plc to Present at UBS Virtual Global Healthcare Conference

    Wednesday, May 20, 2020

  • 5 May 2020

    ICON appoints new Chief Medical Officer

    ICON announces the appointment of Dr Kristen Buck as the new Chief Medical Officer (CMO).

  • 22 April 2020

    ICON Reports First Quarter 2020 Results

    Reported revenue of $715.1 million representing a 6.0% YoY increase or 6.5% on a constant currency basis. Net business wins of $867 million; a book to bill of 1.21.

  • 9 April 2020

    ICON wins multiple categories in 2020 CRO Leadership Awards third year in a row

    ICON recognised for specialised services offering across product development lifecycle, winning five awards overall.

  • 3 April 2020

    ICON signs new Service Agreement with Pfizer

    Agreement builds on the companies' existing relationship, under which ICON provides global expertise in the planning, execution, management and conduct of clinical trials.

  • 23 March 2020

    ICON launches the Coronavirus Observatory

    The Coronavirus Observatory applies powerful AI analysis and data visualisation to COVID-19 news and social media, providing updates on the latest vaccine trials.

  • 3 March 2020

    ICON plc to Present at Barclays Global Healthcare Conference 2020

    The presentation will be webcast live from 10.15am EDT, Tuesday, March 10, 2020.

  • 1
  • 2
  • 3
  • 4
  • 5
  • ...
  • 11
In this section
In this section
  • Press Releases
  • In the News
  • Events
    • Industry Events
    • Webinars
    • Workshops
  • Mediakit
    • Facts and figures
    • ICON Spokespeople
  • Social Media
  • Awards
  • ICON supports Pfizer and BioNTech on COVID-19 vaccine trial
  • Webinar: FT Digital Dialogues: Building resilience in pharma R&D by decentralising and digitising

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media

What’s happening in ICON

ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Services
  • Insights
  • Innovation
  • Content Preferences
ICON For
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press Releases
  • Mediakit
  • Events
  • Social Media Dashboard
  • Coronavirus Observatory
  • LinkedIn
  • Twitter
  • Facebook
  • Youtube
  • © 2021 ICON plc
  • Disclaimer
  • Privacy
  • Site Cookies

Connect with us

Contact us Submit proposal request Update Email Preferences Global office locator ICON on social media